RALEIGH, N.C., Oct. 6, 2017 /PRNewswire/ -- BioDelivery
Sciences International, Inc. (NASDAQ: BDSI) participated in a round
table meeting convened this week in Washington, D.C. by the U.S. Department of
Health and Human Services (HHS) to discuss efforts to advance pain
management therapies and the treatment of opioid dependence as well
as advancing alternative therapies. BDSI was represented by its
Vice Chairman, President and Chief Executive Officer, Dr.
Mark A. Sirgo, who discussed BDSI's
work to develop novel products, such as buprenorphine, for the
treatment of chronic pain and opioid dependence.
"I was pleased to participate in this important discussion
convened by HHS, and we appreciate the opportunity to share the
work BDSI is doing to advance effective pain management therapies
and the treatment of opioid dependence in light of the current
opioid epidemic we face," said Dr. Sirgo. "BDSI has been
focused on bringing healthcare providers alternative formulations
of buprenorphine based on knowledge that it provides an effective,
Schedule III alternative to other more addictive opioids. We
recognize the seriousness of the conversation about opioids and
their role in pain management in this country and the need to
continue to provide and develop effective and safer options for the
nearly 100 million Americans who currently suffer from chronic pain
as well as those needing support to address their addiction to
opioids, and we are pleased to provide products that can be part of
the solution."
During the round table discussion Dr. Sirgo introduced BDSI,
highlighted its innovative drug delivery technology and products,
and expressed the company's mission to develop therapies to treat
pain as well as opioid dependence.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a
specialty pharmaceutical company with a focus in the areas of pain
management and addiction medicine. BDSI is utilizing its
novel and proprietary BioErodible MucoAdhesive (BEMA®)
technology and other drug delivery technologies to develop and
commercialize, either on its own or in partnership with third
parties, new applications of proven therapies aimed at addressing
important unmet medical needs.
BDSI's marketed products and those in development address
serious and debilitating conditions such as breakthrough cancer
pain, chronic pain and opioid dependence. BDSI's headquarters
is in Raleigh, North Carolina.
For more information, please visit or follow us:
Internet:
|
www.bdsi.com
|
Facebook:
|
Facebook.com/BioDeliverySI
|
Twitter:
|
@BioDeliverySI
|
BUNAVAIL® (buprenorphine and naloxone) buccal film
(CIII) and BELBUCA® (buprenorphine) buccal film (CIII)
are marketed in the U.S. by BioDelivery Sciences.
ONSOLIS® (fentanyl buccal soluble film) (CII) is
licensed in the U.S. to Collegium Pharmaceutical pursuant to the
U.S. licensing and development agreement between BDSI and
Collegium. For full prescribing information and important safety
information on BDSI products, including BOXED WARNINGS for ONSOLIS,
please visit www.bdsi.com where the Company promptly
posts press releases, SEC filings and other important information
or contact the Company at (800) 469-0261. For full
prescribing and safety information on BELBUCA, please visit
www.belbuca.com and for full prescribing and safety
information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentations described herein, and any
statements of employees, representatives and partners of
BioDelivery Sciences International, Inc. (the "Company") related
thereto contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and
uncertainties. Such statements may include, without
limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other
statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results (including, without limitation,
the results of the Company's commercialization programs for BELBUCA
and BUNAVAIL) may differ significantly from those set forth or
implied in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®,
BUNAVAIL® and BELBUCA® are registered
trademarks of BioDelivery Sciences International, Inc. The
BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks
owned by BioDelivery Sciences International, Inc. All other
trademarks and tradenames are owned by their respective owners.
© 2017 BioDelivery Sciences International, Inc. All rights
reserved.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biodelivery-sciences-participates-in-us-department-of-health-and-human-services-round-table-discussion-on-pain-management-and-opioid-dependence-300532339.html
SOURCE BioDelivery Sciences International, Inc.